Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMerge: Risankizumab vs Secukinumab in Plaque Psoriasis
NCT03478787Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2018
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of risankizumab in plaque psoriasis, sponsored by AbbVie Inc.. Started May 2018; status: completed.
02
Drugs
risankizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03478787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03478787.